112 related articles for article (PubMed ID: 21651893)
1. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
[TBL] [Abstract][Full Text] [Related]
2. Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
Li Z; Jia K; Duan Y; Wang D; Zhou Z; Dong S
Mol Med Rep; 2017 Nov; 16(5):7835-7840. PubMed ID: 28944835
[TBL] [Abstract][Full Text] [Related]
3. Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice.
Dong Z; Yan L; Huang G; Zhang L; Mei B; Meng B
Neuroscience; 2014 Jun; 270():58-68. PubMed ID: 24699228
[TBL] [Abstract][Full Text] [Related]
4. A novel derivative of xanomeline improves fear cognition in aged mice.
Si W; Zhang X; Niu Y; Yu H; Lei X; Chen H; Cao X
Neurosci Lett; 2010 Apr; 473(2):115-9. PubMed ID: 20178835
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice.
Gu F; Zhu M; Shi J; Hu Y; Zhao Z
Neurosci Lett; 2008 Jul; 440(1):44-8. PubMed ID: 18539391
[TBL] [Abstract][Full Text] [Related]
6. A novel derivative of xanomeline improved memory function in aged mice.
Cui YH; Si W; Yin L; An SM; Jin J; Deng SN; Cao XH
Neurosci Bull; 2008 Aug; 24(4):251-7. PubMed ID: 18668154
[TBL] [Abstract][Full Text] [Related]
7. Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice.
Wu P; Shen Q; Dong S; Xu Z; Tsien JZ; Hu Y
Neurobiol Aging; 2008 Oct; 29(10):1502-11. PubMed ID: 17499883
[TBL] [Abstract][Full Text] [Related]
8. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
9. Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2.
Zhu M; Gu F; Shi J; Hu J; Hu Y; Zhao Z
Free Radic Biol Med; 2008 Nov; 45(10):1493-9. PubMed ID: 18822370
[TBL] [Abstract][Full Text] [Related]
10. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
11. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
12. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
13. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
15. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
16. Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice.
Jiang X; Zhang D; Shi J; Chen Y; Zhang P; Mei B
J Alzheimers Dis; 2009; 18(3):515-23. PubMed ID: 19584449
[TBL] [Abstract][Full Text] [Related]
17. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
19. Trans-cinnamaldehyde improves neuroinflammation-mediated NMDA receptor dysfunction and memory deficits through blocking NF-κB pathway in presenilin1/2 conditional double knockout mice.
Zhao Y; Deng H; Li K; Wang L; Wu Y; Dong X; Wang X; Chen Y; Xu Y
Brain Behav Immun; 2019 Nov; 82():45-62. PubMed ID: 31376499
[TBL] [Abstract][Full Text] [Related]
20. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
